Title: | Which Benefits Can Justify Risks in Research? |
Author: |
|
Date: | 2024 |
Language: | English |
Scope: | 1116169 |
Series: | American Journal of Bioethics; () |
ISSN: | 1526-5161 |
DOI: | 10.1080/15265161.2023.2296404 |
Subject: | decentralized clinical trials; Ethics committees; IRB (Institutional Review Board); research benefits; research ethics; risk/benefit analysis; Issues, Ethics and Legal Aspects; Health Policy |
URI: | https://hdl.handle.net/20.500.11815/5188 |
Citation:van Rijssel , T I , van Thiel , G J M W , Gardarsdottir , H & van Delden , J J M 2024 , ' Which Benefits Can Justify Risks in Research? ' , American Journal of Bioethics . https://doi.org/10.1080/15265161.2023.2296404
|
|
Abstract:Research ethics committees (RECs) evaluate whether the risk-benefit ratio of a study is acceptable. Decentralized clinical trials (DCTs) are a novel approach for conducting clinical trials that potentially bring important benefits for research, including several collateral benefits. The position of collateral benefits in risk-benefit assessments is currently unclear. DCTs raise therefore questions about how these benefits should be assessed. This paper aims to reconsider the different types of research benefits, and their position in risk-benefit assessments. We first propose a categorization of research benefits, based on the types of benefits that can be distinguished from the literature and ethical guidelines. Secondly, we will reconsider the position of collateral benefits. We argue that these benefits are not fundamentally different from other benefits of research and can therefore be included in risk-benefit assessments of DCTs.
|
|
Description:Publisher Copyright: © 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.
|